ERAS
Erasca, Inc.
Price Chart
Latest Quote
$21.26
+1.76 (+9.03%)
Current Price
| Previous Close | $19.50 |
| Open | $19.46 |
| Day High | $21.60 |
| Day Low | $19.46 |
| Volume | 8,593,464 |
Stock Information
| Shares Outstanding | 347.13M |
| Total Debt | $45.95M |
| Cash Equivalents | $243.79M |
| Net Income | $-277.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $6.65B |
| EPS (TTM) | $-0.94 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $5.76B |
| Income | $-277.02M |
| Book/sh | $1.27 |
| Cash/sh | $0.70 |
| Employees | 103 |
Financial Ratios
| Quick Ratio | 9.27 |
| Current Ratio | 9.52 |
| Debt/Eq | 11.68 |
Returns & Margins
| ROA | -17.92% |
| ROE | -69.86% |
Ownership
| Insider Ownership | 9.69% |
| Institutional Ownership | 85.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -34.67 |
| P/B | 15.14 |
Analyst Data
| Recommendation | buy |
| Target Price | $21.90 |
Technical Indicators
| SMA20 | $17.67 |
| SMA50 | $14.31 |
| SMA200 | $10.08 |
| RSI | 63.19 |
| ATR | 1.4672 |
| Shares Float | 207.89M |
| Short Float | 11.66% |
| Short Ratio | 5.04 |
| Volatility | 0.67 |
| Rel Volume | 1.00 |
Performance History
| Week | +3.45% |
| Month | +43.27% |
| Quarter | +5.16% |
| 6 Months | +130.69% |
| YTD | +433.98% |
| Year | +1231.25% |
| 3 Years | +589.57% |
| 10 Years | +9.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $19.17 | 6,704,400 |
| 2026-07-16 | $19.02 | 9,316,300 |
| 2026-07-15 | $21.26 | 9,044,000 |
| 2026-07-14 | $19.50 | 10,704,500 |
| 2026-07-13 | $17.90 | 2,555,100 |
| 2026-07-10 | $18.53 | 3,018,700 |
| 2026-07-09 | $19.18 | 4,199,600 |
| 2026-07-08 | $18.87 | 5,956,700 |
| 2026-07-07 | $18.36 | 5,241,600 |
| 2026-07-06 | $18.85 | 4,539,600 |
| 2026-07-02 | $18.47 | 4,095,200 |
| 2026-07-01 | $17.92 | 3,890,000 |
| 2026-06-30 | $18.32 | 5,407,400 |
| 2026-06-29 | $18.29 | 7,991,600 |
| 2026-06-26 | $16.01 | 18,335,400 |
| 2026-06-25 | $14.95 | 6,132,200 |
| 2026-06-24 | $15.05 | 4,122,500 |
| 2026-06-23 | $15.07 | 4,294,700 |
| 2026-06-22 | $15.08 | 8,996,600 |
| 2026-06-18 | $13.67 | 9,642,000 |
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
đ° Latest News
Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns
Simply Wall St. âĸ 2026-07-16T03:24:20Z
Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?
Simply Wall St. âĸ 2026-07-15T15:13:39Z
Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers
Simply Wall St. âĸ 2026-07-15T14:10:17Z
Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results
Insider Monkey âĸ 2026-07-14T23:40:45Z
Robinhood and 4 More Stocks That Were Just Added to This Firmâs âTop Picksâ List
Barrons.com âĸ 2026-07-02T18:44:00Z
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
Zacks âĸ 2026-07-02T14:50:00Z
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Zacks âĸ 2026-07-02T14:46:00Z
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Zacks âĸ 2026-07-02T14:43:00Z
Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors
MT Newswires âĸ 2026-06-23T20:44:06ZErasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials
Insider Monkey âĸ 2026-06-11T10:20:37Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $131,405,000 | $157,087,000 | $141,525,000 | $145,450,000 |
| Other Income Expense | $-9,748,000 | $-24,656,000 | $-229,000 | $-102,257,000 |
| Other Non Operating Income Expenses | $-248,000 | $-2,156,000 | $-229,000 | $-257,000 |
| Net Non Operating Interest Income Expense | $16,607,000 | $20,093,000 | $16,712,000 | $4,902,000 |
| Operating Expense | $131,405,000 | $157,087,000 | $141,525,000 | $145,450,000 |
| General And Administrative Expense | $38,551,000 | $41,728,000 | $37,704,000 | $32,993,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Net Interest Income | $16,607,000 | $20,093,000 | $16,712,000 | $4,902,000 |
| Interest Income | $16,607,000 | $20,093,000 | $16,712,000 | $4,902,000 |
| Normalized Income | $-115,046,000 | $-139,150,000 | $-125,042,000 | $-140,805,000 |
| Net Income From Continuing And Discontinued Operation | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Total Operating Income As Reported | $-140,905,000 | $-179,587,000 | $-141,525,000 | $-247,450,000 |
| Net Income Common Stockholders | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Net Income | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Net Income Including Noncontrolling Interests | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Net Income Continuous Operations | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Pretax Income | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Special Income Charges | $-9,500,000 | $-22,500,000 | $0 | $-102,000,000 |
| Interest Income Non Operating | $16,607,000 | $20,093,000 | $16,712,000 | $4,902,000 |
| Operating Income | $-131,405,000 | $-157,087,000 | $-141,525,000 | $-145,450,000 |
| Per Share | ||||
| Diluted EPS | $-0.44 | $-0.69 | $-0.83 | $-1.99 |
| Basic EPS | $-0.44 | $-0.69 | $-0.83 | $-1.99 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-118,798,000 | $-130,782,000 | $-137,793,000 | $-40,809,000 |
| Total Unusual Items | $-9,500,000 | $-22,500,000 | $0 | $-102,000,000 |
| Total Unusual Items Excluding Goodwill | $-9,500,000 | $-22,500,000 | $0 | $-102,000,000 |
| Reconciled Depreciation | $3,107,000 | $3,805,000 | $3,732,000 | $2,641,000 |
| EBITDA (Bullshit earnings) | $-128,298,000 | $-153,282,000 | $-137,793,000 | $-142,809,000 |
| EBIT | $-131,405,000 | $-157,087,000 | $-141,525,000 | $-145,450,000 |
| Diluted Average Shares | $283,533,696 | $233,817,916 | $150,184,994 | $122,024,848 |
| Basic Average Shares | $283,533,696 | $233,817,916 | $150,184,994 | $122,024,848 |
| Diluted NI Availto Com Stockholders | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Other Special Charges | $9,500,000 | $22,500,000 | - | $102,000,000 |
| Research And Development | $92,854,000 | $115,359,000 | $103,821,000 | $112,457,000 |
| Selling General And Administration | $38,551,000 | $41,728,000 | $37,704,000 | $32,993,000 |
| Other Gand A | $38,551,000 | $41,728,000 | $37,704,000 | $32,993,000 |
Fetched: 2026-07-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Total Assets | $396,154,000 | $502,526,000 | $395,297,000 | $514,909,000 |
| Total Non Current Assets | $109,915,000 | $193,733,000 | $74,621,000 | $70,413,000 |
| Other Non Current Assets | $1,861,000 | $3,030,000 | $4,791,000 | $5,180,000 |
| Investmentin Financial Assets | $65,721,000 | $142,164,000 | $9,642,000 | $0 |
| Current Assets | $286,239,000 | $308,793,000 | $320,676,000 | $444,496,000 |
| Other Current Assets | $10,164,000 | $10,484,000 | $8,326,000 | $8,876,000 |
| Cash Cash Equivalents And Short Term Investments | $276,075,000 | $298,309,000 | $312,350,000 | $435,620,000 |
| Cash And Cash Equivalents | $73,805,000 | $67,739,000 | $93,075,000 | $284,217,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $47,139,000 | $51,889,000 | $55,859,000 | $55,098,000 |
| Long Term Debt And Capital Lease Obligation | $42,073,000 | $47,270,000 | $51,889,000 | $53,793,000 |
| Current Debt And Capital Lease Obligation | $5,066,000 | $4,619,000 | $3,970,000 | $1,305,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $70,983,000 | $79,027,000 | $78,611,000 | $103,056,000 |
| Total Non Current Liabilities Net Minority Interest | $42,472,000 | $47,632,000 | $52,455,000 | $54,366,000 |
| Other Non Current Liabilities | $399,000 | $362,000 | $566,000 | $573,000 |
| Current Liabilities | $28,511,000 | $31,395,000 | $26,156,000 | $48,690,000 |
| Payables And Accrued Expenses | $11,372,000 | $16,125,000 | $11,411,000 | $36,300,000 |
| Payables | $981,000 | $468,000 | $2,000,000 | $23,049,000 |
| Accounts Payable | $981,000 | $468,000 | $2,000,000 | $23,049,000 |
| Other Current Liabilities | - | - | $464,000 | $1,690,000 |
| Equity | ||||
| Common Stock Equity | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Total Equity Gross Minority Interest | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Stockholders Equity | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Gains Losses Not Affecting Retained Earnings | $628,000 | $405,000 | $77,000 | $-1,041,000 |
| Other Equity Adjustments | $628,000 | $405,000 | $77,000 | $-1,041,000 |
| Retained Earnings | $-892,209,000 | $-767,663,000 | $-606,013,000 | $-480,971,000 |
| Other | ||||
| Ordinary Shares Number | $284,159,076 | $283,218,344 | $151,462,103 | $149,333,258 |
| Share Issued | $284,159,076 | $283,218,344 | $151,462,103 | $149,333,258 |
| Tangible Book Value | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Invested Capital | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Working Capital | $257,728,000 | $277,398,000 | $294,520,000 | $395,806,000 |
| Capital Lease Obligations | $47,139,000 | $51,889,000 | $55,859,000 | $55,098,000 |
| Total Capitalization | $325,171,000 | $423,499,000 | $316,686,000 | $411,853,000 |
| Additional Paid In Capital | $1,216,724,000 | $1,190,729,000 | $922,607,000 | $893,850,000 |
| Capital Stock | $28,000 | $28,000 | $15,000 | $15,000 |
| Common Stock | $28,000 | $28,000 | $15,000 | $15,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $42,073,000 | $47,270,000 | $51,889,000 | $53,793,000 |
| Current Capital Lease Obligation | $5,066,000 | $4,619,000 | $3,970,000 | $1,305,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,073,000 | $10,651,000 | $10,311,000 | $9,395,000 |
| Current Accrued Expenses | $10,391,000 | $15,657,000 | $9,411,000 | $13,251,000 |
| Investments And Advances | $65,721,000 | $142,164,000 | $9,642,000 | $0 |
| Available For Sale Securities | $65,721,000 | $142,164,000 | $9,642,000 | - |
| Net PPE | $42,333,000 | $48,539,000 | $60,188,000 | $65,233,000 |
| Accumulated Depreciation | $-12,661,000 | $-10,009,000 | $-7,232,000 | $-3,500,000 |
| Gross PPE | $54,994,000 | $58,548,000 | $67,420,000 | $68,733,000 |
| Leases | $16,313,000 | $16,313,000 | $18,173,000 | $17,837,000 |
| Other Properties | $4,429,000 | $4,741,000 | $5,620,000 | $4,815,000 |
| Machinery Furniture Equipment | $5,222,000 | $5,276,000 | $5,766,000 | $5,663,000 |
| Buildings And Improvements | $29,030,000 | $32,218,000 | $37,861,000 | $40,418,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $202,270,000 | $230,570,000 | $219,275,000 | $151,403,000 |
| Construction In Progress | - | - | - | $0 |
Fetched: 2026-07-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-105,083,000 | $-131,977,000 | $-122,992,000 | $-119,815,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-95,455,000 | $-109,417,000 | $-101,217,000 | $-103,264,000 |
| Cash Flow From Continuing Operating Activities | $-95,455,000 | $-109,417,000 | $-101,217,000 | $-103,264,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-9,628,000 | $-22,560,000 | $-21,775,000 | $-16,551,000 |
| Investing Cash Flow | $100,425,000 | $-156,616,000 | $-91,220,000 | $-71,081,000 |
| Cash Flow From Continuing Investing Activities | $100,425,000 | $-156,616,000 | $-91,220,000 | $-71,081,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $239,061,000 | $0 | $95,251,000 |
| Financing Cash Flow | $1,096,000 | $240,697,000 | $1,295,000 | $98,075,000 |
| Cash Flow From Continuing Financing Activities | $1,096,000 | $240,697,000 | $1,295,000 | $98,075,000 |
| Net Common Stock Issuance | $0 | $239,061,000 | $0 | $95,251,000 |
| Common Stock Issuance | $0 | $239,061,000 | $0 | $95,251,000 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| End Cash Position | $74,213,000 | $68,147,000 | $93,483,000 | $284,625,000 |
| Beginning Cash Position | $68,147,000 | $93,483,000 | $284,625,000 | $360,895,000 |
| Changes In Cash | $6,066,000 | $-25,336,000 | $-191,142,000 | $-76,270,000 |
| Proceeds From Stock Option Exercised | $1,096,000 | $1,636,000 | $1,295,000 | $2,824,000 |
| Net Investment Purchase And Sale | $110,053,000 | $-134,056,000 | $-69,445,000 | $-54,530,000 |
| Sale Of Investment | $261,027,000 | $269,325,000 | $244,945,000 | $79,800,000 |
| Purchase Of Investment | $-150,974,000 | $-403,381,000 | $-314,390,000 | $-134,330,000 |
| Net Intangibles Purchase And Sale | $-9,500,000 | $-22,500,000 | $-20,000,000 | $-2,000,000 |
| Purchase Of Intangibles | $-9,500,000 | $-22,500,000 | $-20,000,000 | $-2,000,000 |
| Net PPE Purchase And Sale | $-128,000 | $-60,000 | $-1,775,000 | $-14,551,000 |
| Purchase Of PPE | $-128,000 | $-60,000 | $-1,775,000 | $-14,551,000 |
| Change In Working Capital | $-3,328,000 | $1,735,000 | $813,000 | $15,785,000 |
| Change In Other Working Capital | $-1,862,000 | $-732,000 | $3,061,000 | $13,703,000 |
| Change In Payables And Accrued Expense | $-3,255,000 | $4,864,000 | $-3,187,000 | $5,694,000 |
| Change In Accrued Expense | $-3,768,000 | $6,396,000 | $-2,301,000 | $5,018,000 |
| Change In Payable | $513,000 | $-1,532,000 | $-886,000 | $676,000 |
| Change In Account Payable | $513,000 | $-1,532,000 | $-886,000 | $676,000 |
| Change In Prepaid Assets | $1,789,000 | $-2,397,000 | $939,000 | $-3,612,000 |
| Other Non Cash Items | $9,500,000 | $22,500,000 | - | $102,000,000 |
| Stock Based Compensation | $24,899,000 | $26,973,000 | $26,231,000 | $20,109,000 |
| Asset Impairment Charge | $0 | $6,810,000 | $0 | - |
| Amortization Of Securities | $-5,087,000 | $-9,590,000 | $-6,951,000 | $-994,000 |
| Depreciation Amortization Depletion | $3,107,000 | $3,805,000 | $3,732,000 | $2,641,000 |
| Depreciation And Amortization | $3,107,000 | $3,805,000 | $3,732,000 | $2,641,000 |
| Net Income From Continuing Operations | $-124,546,000 | $-161,650,000 | $-125,042,000 | $-242,805,000 |
| Depreciation | - | - | - | - |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-07-06